Daewon Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1958-01-07
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.daewonpharm.com
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
Phase 2
- Conditions
- Acute and Chronic Gastric Inflammation Patients
- Interventions
- Drug: PlaceboDrug: DW-3101_150mgDrug: DW-3101_300mgDrug: DW-3101_600mg
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02386007
Study of Freefol-MCT PKPD in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02384720
Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02380976
Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT02375633
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT02368613
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: DW330SR 45mgDrug: DW1030 75mg
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Registration Number
- NCT02071381
- Locations
- 🇰🇷
Asan Medical Center IRB, Seoul, Korea, Republic of
Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
Phase 3
Completed
- Conditions
- Acute Back Pain
- Interventions
- Drug: Myonal Tab.(eperisone HCl) 50mgDrug: DW-1030(eperisone HCl) 75mgDrug: Placebo drug of DW-1030Drug: Placebo drug of Myonal Tab.
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT02040415
Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery
Phase 3
Completed
- Conditions
- Acute Toothache Patients Above Moderate Pain After Teeth Extraction Surgery
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT01920386
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Males
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Registration Number
- NCT01870102
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
Phase 3
Completed
- Conditions
- PelubiprofenCelebrexRheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01781702
© Copyright 2025. All Rights Reserved by MedPath